{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:32:43Z","timestamp":1789399963513,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["2016"],"award-info":[{"award-number":["2016"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["2019"],"award-info":[{"award-number":["2019"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["SIRIC2016"],"award-info":[{"award-number":["SIRIC2016"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PLBIO2018"],"award-info":[{"award-number":["PLBIO2018"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02697-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:01:12Z","timestamp":1776758472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemia"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-351X","authenticated-orcid":false,"given":"Fanny","family":"Gonzales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Peyrouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djohana","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihad","family":"Boukrout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Houdiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-4219","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Sevrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-6286","authenticated-orcid":false,"given":"Nicolas","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent-Philippe","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Geles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-2577","authenticated-orcid":false,"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Roumier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7820-8026","authenticated-orcid":false,"given":"Meyling","family":"Cheok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser, O. et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur. J. Cancer 48, 3257\u20133266 (2012).","journal-title":"Eur. J. Cancer"},{"key":"2697_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/gcc.22750","volume":"58","author":"IS Tiong","year":"2019","unstructured":"Tiong, I. S. & Wei, A. H. New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes Cancer 58, 903\u2013914 (2019).","journal-title":"Genes Chromosomes Cancer"},{"key":"2697_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"2697_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret, H. & Gardin, C. An update of current treatments for adult acute myeloid leukemia. Blood 127, 53\u201361 (2016).","journal-title":"Blood"},{"key":"2697_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"2697_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol, F. & Ganser, A. Treatment of relapsed acute myeloid leukemia. Curr. Treat. Options Oncol. 21, 66 (2020).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2697_CR7","doi-asserted-by":"publisher","first-page":"100850","DOI":"10.1016\/j.blre.2021.100850","volume":"50","author":"E O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly, E., Zeinabad, H. A. & Szegezdi, E. Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities. Blood Rev. 50, 100850 (2021).","journal-title":"Blood Rev."},{"key":"2697_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104\u2013108 (2017).","journal-title":"Nature"},{"key":"2697_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea, D. A. & Jordan, C. T. Therapeutic targeting of acute myeloid leukemia stem cells. Blood 129, 1627\u20131635 (2017).","journal-title":"Blood"},{"key":"2697_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"2697_CR11","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","volume":"106","author":"DC Taussig","year":"2005","unstructured":"Taussig, D. C. et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106, 4086\u20134092 (2005).","journal-title":"Blood"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan, C. T. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777\u201384 (2000).","journal-title":"Leukemia"},{"key":"2697_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med 12, 1167\u20131174 (2006).","journal-title":"Nat. Med"},{"key":"2697_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"2697_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"2697_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige, Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708\u2013717 (2010).","journal-title":"Cell Stem Cell"},{"key":"2697_CR17","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen, A. et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110, 2659\u201366 (2007).","journal-title":"Blood"},{"key":"2697_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1634\/stemcells.2007-0861","volume":"26","author":"B Moshaver","year":"2008","unstructured":"Moshaver, B. et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 26, 3059\u20133067 (2008).","journal-title":"Stem Cells"},{"key":"2697_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138\u2013152 (2011).","journal-title":"Cancer Cell"},{"key":"2697_CR20","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1182\/blood.V89.9.3104","volume":"89","author":"A Blair","year":"1997","unstructured":"Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M. & Sutherland, H. J. Lack of expression of Thy-1 (CD90) on Acute Myeloid Leukemia Cells With Long-term Proliferative Ability In Vitro And In Vivo. Blood 89, 3104\u20133112 (1997).","journal-title":"Blood"},{"key":"2697_CR21","first-page":"4007","volume":"10","author":"R Oren","year":"1990","unstructured":"Oren, R., Takahashi, S., Doss, C., Levy, R. & Levy, S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell Biol. 10, 4007\u201315 (1990).","journal-title":"Mol. Cell Biol."},{"key":"2697_CR22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1128\/MCB.26.4.1373-1385.2006","volume":"26","author":"T Shoham","year":"2006","unstructured":"Shoham, T., Rajapaksa, R., Kuo, C. C., Haimovich, J. & Levy, S. Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol. Cell Biol. 26, 1373\u201385 (2006).","journal-title":"Mol. Cell Biol."},{"key":"2697_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tcb.2009.06.004","volume":"19","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2009","unstructured":"Y\u00e1\u00f1ez-M\u00f3, M., Barreiro, O., Gordon-Alonso, M., Sala-Vald\u00e9s, M. & S\u00e1nchez-Madrid, F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 19, 434\u2013446 (2009).","journal-title":"Trends Cell Biol."},{"key":"2697_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrm1736","volume":"6","author":"ME Hemler","year":"2005","unstructured":"Hemler, M. E. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 6, 801\u2013811 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2697_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15459-7","volume":"11","author":"R Umeda","year":"2020","unstructured":"Umeda, R. et al. Structural insights into tetraspanin CD9 function. Nat. Commun. 11, 1606 (2020).","journal-title":"Nat. Commun."},{"key":"2697_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2016.09.056","volume":"167","author":"B Zimmerman","year":"2016","unstructured":"Zimmerman, B. et al. Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket. Cell 167, 1041\u20131051.e11 (2016).","journal-title":"Cell"},{"key":"2697_CR27","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.4049\/jimmunol.149.9.2841","volume":"149","author":"LE Bradbury","year":"1992","unstructured":"Bradbury, L. E., Kansas, G. S., Levy, S., Evans, R. L. & Tedder, T. F. The CD19\/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149, 2841\u20132850 (1992).","journal-title":"J. Immunol."},{"key":"2697_CR28","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52337","volume":"9","author":"KJ Susa","year":"2020","unstructured":"Susa, K. J., Seegar, T. C., Blacklow, S. C. & Kruse, A. C. A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking. Elife 9, e52337 (2020).","journal-title":"Elife"},{"key":"2697_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.20190186","volume":"216","author":"F Vences-Catal\u00e1n","year":"2019","unstructured":"Vences-Catal\u00e1n, F. et al. CD81 is a novel immunotherapeutic target for B cell lymphoma. J. Exp. Med. 216, 1497\u20131508 (2019).","journal-title":"J. Exp. Med."},{"key":"2697_CR30","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/bloodadvances.2020001592","volume":"4","author":"A Quagliano","year":"2020","unstructured":"Quagliano, A., Gopalakrishnapillai, A., Kolb, E. A. & Barwe, S. P. CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Adv. 4, 4393\u20134405 (2020).","journal-title":"Blood Adv."},{"key":"2697_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018961118","volume":"118","author":"F Vences-Catal\u00e1n","year":"2021","unstructured":"Vences-Catal\u00e1n, F. et al. Targeting the tetraspanin CD81 reduces cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA. 118, e2018961118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2697_CR32","doi-asserted-by":"publisher","first-page":"62377","DOI":"10.18632\/oncotarget.11481","volume":"7","author":"T Boyer","year":"2016","unstructured":"Boyer, T. et al. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget 7, 62377\u201362385 (2016).","journal-title":"Oncotarget"},{"key":"2697_CR33","doi-asserted-by":"publisher","first-page":"114260","DOI":"10.1016\/j.celrep.2024.114260","volume":"43","author":"M-E Bordeleau","year":"2024","unstructured":"Bordeleau, M.-E. et al. Immunotherapeutic targeting of surfaceome heterogeneity in AML. Cell Rep. 43, 114260 (2024).","journal-title":"Cell Rep."},{"key":"2697_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"2697_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"2697_CR36","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).","journal-title":"Sci. Signal"},{"key":"2697_CR37","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477\u20136489 (2005).","journal-title":"J. Immunol."},{"key":"2697_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.19","volume":"5","author":"E Saland","year":"2015","unstructured":"Saland, E. et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J. 5, e297 (2015).","journal-title":"Blood Cancer J."},{"key":"2697_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1532\/IJH97.05144","volume":"82","author":"JE Dick","year":"2005","unstructured":"Dick, J. E. & Lapidot, T. Biology of normal and acute myeloid leukemia stem cells. Int J. Hematol. 82, 389\u2013396 (2005).","journal-title":"Int J. Hematol."},{"key":"2697_CR40","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/sj.bjc.6600912","volume":"88","author":"N Cordes","year":"2003","unstructured":"Cordes, N. & Van Beuningen, D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3\u03b2 (GSK-3\u03b2) in vitro. Br. J. Cancer 88, 1470\u20131479 (2003).","journal-title":"Br. J. Cancer"},{"key":"2697_CR41","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2697_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SWK Ng","year":"2016","unstructured":"Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"2697_CR43","doi-asserted-by":"publisher","first-page":"110623","DOI":"10.1016\/j.cellsig.2023.110623","volume":"106","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. LAPTM4B promotes AML progression through regulating RPS9\/STAT3 axis. Cell Signal 106, 110623 (2023).","journal-title":"Cell Signal"},{"key":"2697_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353\u2013366 (2023).","journal-title":"Haematologica"},{"key":"2697_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158\u2013173 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2697_CR46","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas, D. & Majeti, R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129, 1577\u20131585 (2017).","journal-title":"Blood"},{"key":"2697_CR47","doi-asserted-by":"crossref","unstructured":"Boyer, T. et al. Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. J Vis Exp. 26, 56976 (2018).","DOI":"10.3791\/56976-v"},{"key":"2697_CR48","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/leu.2016.265","volume":"31","author":"O Nibourel","year":"2017","unstructured":"Nibourel, O. et al. Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia 31, 555\u2013564 (2017).","journal-title":"Leukemia"},{"key":"2697_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41375-018-0227-5","volume":"33","author":"N Duployez","year":"2019","unstructured":"Duployez, N. et al. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia 33, 348\u2013357 (2019).","journal-title":"Leukemia"},{"key":"2697_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2017.10.008","volume":"20","author":"CC Zhang","year":"2018","unstructured":"Zhang, C. C. et al. Gemtuzumab Ozogamicin (GO) inclusion to induction chemotherapy eliminates leukemic initiating cells and significantly improves survival in mouse models of acute myeloid leukemia. Neoplasia 20, 1\u201311 (2018).","journal-title":"Neoplasia"},{"key":"2697_CR51","doi-asserted-by":"publisher","first-page":"a036251","DOI":"10.1101\/cshperspect.a036251","volume":"10","author":"K Mitchell","year":"2020","unstructured":"Mitchell, K. & Steidl, U. Targeting immunophenotypic markers on leukemic stem cells: how lessons from current approaches and advances in the leukemia stem cell (LSC) model can inform better strategies for treating acute myeloid leukemia (AML). Cold Spring Harb. Perspect. Med 10, a036251 (2020).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2697_CR52","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med"},{"key":"2697_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264\u2013278 (2012).","journal-title":"Cell"},{"key":"2697_CR54","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"2697_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2012-04-427039","volume":"121","author":"B Parkin","year":"2013","unstructured":"Parkin, B. et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121, 369\u2013377 (2013).","journal-title":"Blood"},{"key":"2697_CR56","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490\u20136 (2001).","journal-title":"Clin. Cancer Res."},{"key":"2697_CR57","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1084\/jem.185.8.1505","volume":"185","author":"HT Maecker","year":"1997","unstructured":"Maecker, H. T. & Levy, S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med. 185, 1505\u201310 (1997).","journal-title":"J. Exp. Med."},{"key":"2697_CR58","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10875-015-0148-2","volume":"35","author":"F Vences-Catal\u00e1n","year":"2015","unstructured":"Vences-Catal\u00e1n, F. et al. A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression. J. Clin. Immunol. 35, 254\u2013263 (2015).","journal-title":"J. Clin. Immunol."},{"key":"2697_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/febs.14123","volume":"285","author":"EK Paterson","year":"2018","unstructured":"Paterson, E. K. & Courtneidge, S. A. Invadosomes are coming: new insights into function and disease relevance. FEBS J. 285, 8\u201327 (2018).","journal-title":"FEBS J."},{"key":"2697_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ceb.2015.06.007","volume":"36","author":"G Jacquemet","year":"2015","unstructured":"Jacquemet, G., Hamidi, H. & Ivaska, J. Filopodia in cell adhesion, 3D migration and cancer cell invasion. Curr. Opin. Cell Biol. 36, 23\u201331 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2697_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.bbrc.2011.10.121","volume":"415","author":"R Bari","year":"2011","unstructured":"Bari, R. et al. Tetraspanins regulate the protrusive activities of cell membrane. Biochem Biophys. Res Commun. 415, 619\u2013626 (2011).","journal-title":"Biochem Biophys. Res Commun."},{"key":"2697_CR62","doi-asserted-by":"crossref","unstructured":"Termini, C. M. & Gillette, J. M. Tetraspanins function as regulators of cellular signaling. Front. Cell Dev. Biol. 5, 34 (2017).","DOI":"10.3389\/fcell.2017.00034"},{"key":"2697_CR63","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1073\/pnas.89.7.2804","volume":"89","author":"CM Baum","year":"1992","unstructured":"Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A. M. & Peault, B. Isolation of a candidate human hematopoietic stem-cell population. Proc. Natl. Acad. Sci. USA 89, 2804\u20132808 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2697_CR64","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez, F. et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 96, 1792\u20138 (2011).","journal-title":"Haematologica"},{"key":"2697_CR65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33, 64\u201374 (2019).","journal-title":"Leukemia"},{"key":"2697_CR66","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","volume":"97","author":"MR Baer","year":"2001","unstructured":"Baer, M. R. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97, 3574\u20133580 (2001).","journal-title":"Blood"},{"key":"2697_CR67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cyto.b.21745","volume":"96","author":"AE Bras","year":"2019","unstructured":"Bras, A. E. et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry 96, 134\u2013142 (2019).","journal-title":"Cytometry"},{"key":"2697_CR68","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1038\/onc.2010.303","volume":"29","author":"L Li","year":"2010","unstructured":"Li, L. et al. LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K\/AKT signaling. Oncogene 29, 5785\u20135795 (2010).","journal-title":"Oncogene"},{"key":"2697_CR69","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/2643-3230.BCD-24-0342","volume":"6","author":"AGX Zeng","year":"2025","unstructured":"Zeng, A. G. X. et al. Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation. Blood Cancer Discov. 6, 307\u2013324 (2025).","journal-title":"Blood Cancer Discov."},{"key":"2697_CR70","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1038\/sj.onc.1211041","volume":"27","author":"C Didier","year":"2008","unstructured":"Didier, C. et al. G2\/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene 27, 3811\u20133820 (2008).","journal-title":"Oncogene"},{"key":"2697_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64012-5","volume":"10","author":"T Hasezaki","year":"2020","unstructured":"Hasezaki, T., Yoshima, T. & Mine, Y. Anti-CD81 antibodies reduce migration of activated T lymphocytes and attenuate mouse experimental colitis. Sci. Rep. 10, 6969 (2020).","journal-title":"Sci. Rep."},{"key":"2697_CR72","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/cancers15072186","volume":"15","author":"C Bailly","year":"2023","unstructured":"Bailly, C. & Thuru, X. Targeting of tetraspanin CD81 with monoclonal antibodies and small molecules to combat cancers and viral diseases. Cancers 15, 2186 (2023).","journal-title":"Cancers"},{"key":"2697_CR73","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4161\/mabs.25642","volume":"5","author":"V Vexler","year":"2013","unstructured":"Vexler, V. et al. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. MAbs 5, 776\u2013786 (2013).","journal-title":"MAbs"},{"key":"2697_CR74","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1093\/emboj\/16.14.4217","volume":"16","author":"T Miyazaki","year":"1997","unstructured":"Miyazaki, T. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 16, 4217\u20134225 (1997).","journal-title":"EMBO J."},{"key":"2697_CR75","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1172\/JCI39748","volume":"120","author":"MC Van Zelm","year":"2010","unstructured":"Van Zelm, M. C. et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J. Clin. Invest. 120, 1265\u20131274 (2010).","journal-title":"J. Clin. Invest."},{"key":"2697_CR76","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"2697_CR77","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills, R. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15, 986\u2013996 (2014).","journal-title":"Lancet Oncol."},{"key":"2697_CR78","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307\u2013315 (2004).","journal-title":"Bioinformatics"},{"key":"2697_CR79","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"2697_CR80","first-page":"100722","volume":"5","author":"G Yu","year":"2024","unstructured":"Yu, G. Thirteen years of clusterProfiler. Innovation 5, 100722 (2024).","journal-title":"Innovation"},{"key":"2697_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-023-05342-9","volume":"24","author":"Y Liu","year":"2023","unstructured":"Liu, Y. & Li, G. Empowering biologists to decode omics data: the Genekitr R package and web server. BMC Bioinforma. 24, 214 (2023).","journal-title":"BMC Bioinforma."},{"key":"2697_CR82","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Core Team, 2022)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02697-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:05:07Z","timestamp":1776762307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02697-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02697-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}